Idexx Laboratories Inc (IDXX): Long-Term Debt
$450.00M
As of 2025-12-31
-16.4%
3-year compound annual growth
-13.1%
5-year compound annual growth
-2.8%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $450.00M | -27.2% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $617.80M | -11.5% | 2025-02-21, Balance as of period end |
| 2023-12-31 | $698.19M | -9.3% | 2024-02-22, Balance as of period end |
| 2022-12-31 | $769.77M | -9.5% | 2023-02-16, Balance as of period end |
| 2021-12-31 | $850.71M | -6.4% | 2022-02-16, Balance as of period end |
| 2020-12-31 | $909.10M | +30.0% | 2022-02-16, Balance as of period end |
| 2019-12-31 | $699.40M | +16.2% | 2021-02-12, Balance as of period end |
| 2018-12-31 | $601.80M | -0.8% | 2020-02-14, Balance as of period end |
| 2017-12-31 | $606.60M | +2.2% | 2019-02-15, Balance as of period end |
| 2016-12-31 | $593.70M | -0.6% | 2018-02-16, Balance as of period end |
| 2015-12-31 | $597.10M | +70.6% | 2017-02-17, Balance as of period end |
| 2014-12-31 | $350.00M | +131.2% | 2015-02-17, Balance as of period end |
| 2013-12-31 | $151.39M | n/m | 2014-02-18, Balance as of period end |
| 2012-12-31 | $2.50M | -26.8% | 2013-02-19, Balance as of period end |
| 2011-12-31 | $3.42M | n/a | 2012-02-17, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $450.00M | -27.2% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $2.70B | +8.4% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $119.90M | n/a |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $13.12M | +39.0% |
| Immucell Corp (ICCC) | 2025-12-31 | $9.10M | n/a |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $1.28M | -15.3% |
| Volitionrx Ltd (VNRX) | 2025-12-31 | $6.71M | +39.4% |
Compare IDXX, QDEL, MYGN, TKNO side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗